Related Experiment Video
Updated: Apr 28, 2026
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
Clinical value of visually identifiable 18F-fluorodeoxyglucose uptake in primary papillary thyroid microcarcinoma
Seung Ook Hwang1, Sang-Woo Lee2, Jin Koo Kang1
1Department of Surgery, Kyungpook National University School of Medicine, Daegu, Korea.
Objective:
This study evaluates the relationship between visually identifiable (18)F-fluorodeoxyglucose (FDG) uptake in primary papillary thyroid microcarcinoma (PTMC) and tumor aggressiveness.
Study Design:
Historical cohort study.
Setting:
Tertiary care center.
Methods:
Clinicopathological factors and PET/CT findings of 219 PTMC surgical patients who underwent preoperative (18)F-FDG positron emission tomography/computed tomography (PET/CT) were retrospectively reviewed.
Results:
(18)F-FDG uptake was observed in the tumors of 124 (56.6%) patients. Tumor size (odds ratio [OR] = 1.774; 95% confidence interval [CI], 1.416-2.223; P < .0001) and Hashimoto thyroiditis (OR = 2.815; CI, 1.237-6.404; P = .014) independently predicted (18)F-FDG uptake. Tumor size (OR = 1.495; CI, 1.217-1.835; P < .0001) and BRAF(V600E) mutation (OR = 3.320; CI, 1.056-10.432; P = .040) independently predicted extrathyroidal invasion. Multiplicity (OR = 2.375; CI, 1.278-4.415; P = .006) independently predicted central lymph node metastasis.
Conclusion:
(18)F-FDG uptake in PTMC depends on tumor size and Hashimoto thyroiditis. Therefore, preoperative PET/CT for PTMC may not help in evaluating tumor aggressiveness.
